CD36 Deficiency Rescues Lipotoxic Cardiomyopathy

John Yang, Nandakumar Sambandam, Xianlin Han, Richard W. Gross, Michael Courtois, Attila Kovacs, Maria Febbraio, Brian N. Finck, Daniel P. Kelly

Abstract—Obesity-related diabetes mellitus leads to increased myocardial uptake of fatty acids (FAs), resulting in a form of cardiac dysfunction referred to as lipotoxic cardiomyopathy. We have shown previously that chronic activation of the FA-activated nuclear receptor, peroxisome proliferator-activated receptor α (PPARα), is sufficient to drive the metabolic and functional abnormalities of the diabetic heart. Mice with cardiac-restricted overexpression of PPARα (myosin heavy chain [MHC]-PPARα) exhibit myocyte lipid accumulation and cardiac dysfunction. We sought to define the role of the long-chain FA transporter CD36 in the pathophysiology of lipotoxic forms of cardiomyopathy. MHC-PPARα mice were crossed with CD36-deficient mice (MHC-PPARα/CD36−/− mice). The absence of CD36 prevented myocyte triacylglyceride accumulation and cardiac dysfunction in the MHC-PPARα mice under basal conditions and following administration of high-fat diet. Surprisingly, the rescue of the MHC-PPARα phenotype by CD36 deficiency was associated with increased glucose uptake and oxidation rather than changes in FA utilization. As predicted by the metabolic changes, the activation of PPARα target genes involved in myocardial FA-oxidation pathways in the hearts of the MHC-PPARα mice was unchanged in the CD36-deficient background. However, PPARα-mediated suppression of genes involved in glucose uptake and oxidation was reversed in the MHC-PPARα/CD36−/− mice. We conclude that CD36 is necessary for the development of lipotoxic cardiomyopathy in MHC-PPARα mice and that novel therapeutic strategies aimed at reducing CD36-mediated FA uptake show promise for the prevention or treatment of cardiac dysfunction related to obesity and diabetes. (Circ Res. 2007;100:1208-1217.)

Key Words: cardiomyopathy ■ diabetes mellitus ■ fatty acids ■ glucose ■ metabolism

We are witnessing a dramatic increase in the prevalence of obesity, which is driving a pandemic of type 2 diabetes mellitus.1-2 Diabetes is a lethal disease, due in large part to accelerated atherosclerosis and a unique form of myocardial dysfunction.3 Diabetic myocardial disease can occur independent of known causative factors for heart failure and confers increased susceptibility to ischemic damage.4-6 Indeed, the incidence of heart failure is increased in diabetic patients compared with nondiabetic patients following myocardial infarction.7-10

Growing evidence suggests that metabolic derangements, related to the insulin resistant and diabetic state, contribute to diabetic cardiac dysfunction.11 Specifically, derangements in cardiac fuel metabolism have been implicated. The normal adult heart uses both glucose and fatty acid (FA) for ATP production, switching between these energy substrate sources depending on the dietary and physiological conditions.12,13 The capacity of the insulin-resistant and diabetic heart to use glucose as a fuel is markedly diminished. This loss of substrate “flexibility” results in the diabetic heart relying almost exclusively on FAs as its substrate source.11,14 Chronically increased FA utilization is thought to contribute to ventricular dysfunction by increasing mitochondrial oxygen consumption, generation of by reactive species attributable to increased flux through oxidative pathways, or via the toxic effects of accumulated lipid species.15-20 In addition, reduced capacity for glucose oxidation has also been linked to ventricular dysfunction, especially in the ischemic and postischemic heart.13,14,21-23

The metabolic reprogramming of the diabetic heart is driven, in part, by gene-regulatory events. Coordinate activation of genes involved in cellular FA uptake and utilization pathways in the diabetic heart has been shown to occur via the transcription factor peroxisome proliferator-activated receptor α (PPARα).24 PPARα is a FA-activated nuclear receptor that regulates cellular FA transport, esterification, and oxidation.25 Transgenic mice with cardiac-restricted overexpression of PPARα (myosin heavy chain [MHC]-PPARα mice) exhibit a cardiac metabolic phenotype that is strikingly similar to that of the diabetic heart: increased FA utilization and decreased uptake and oxidation of glucose.24 MHC-PPARα mice also exhibit features of lipotoxic cardiomyopathy, including ventricular hypertrophy and dysfunction associated with myocardial lipid accumulation.24 This

Original received October 16, 2006; revision received February 6, 2007; accepted March 7, 2007.
From the Center for Cardiovascular Research (J.Y., N.S., R.W.G., M.C., A.K., D.P.K.) and Departments of Medicine (J.Y., N.S., X.H., R.W.G., M.C., A.K., B.N.F., D.P.K.), Molecular Biology & Pharmacology (R.W.G., D.P.K.), and Pediatrics (D.P.K.), Washington University School of Medicine, St Louis, Mo; and Department of Cell Biology (M.F.), Lerner Research Institute, Cleveland Clinic, Ohio.
Correspondence to Daniel P. Kelly, MD, Center for Cardiovascular Research, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 3086, St Louis, MO 63110. E-mail dkelley@im.wustl.edu
© 2007 American Heart Association, Inc.
Circulation Research is available at http://circres.ahajournals.org
DOI: 10.1161/01.RES.0000264104.25265.b6

1208
pheno type resembles the cardiomyopathy associated with obesity and diabetes. Several animal models of obesity and diabetes, such as the Zucker diabetic fatty (ZDF) rat, also exhibit cardiac myocyte lipid accumulation.26 Cardiomyopathy in MHC-PPARα mice is exacerbated by a high fat (HF) diet enriched in long-chain FA (LCFA) or acute insulin deficiency, states that result in increased delivery of nonesterified FA to the heart.27

We sought to define the role of cellular LCFA import in the cardiomyopathic phenotype of MHC-PPARα mice. To this end, MHC-PPARα mice were crossed with mice deficient for CD36, a membrane-associated transporter that has been shown to facilitate uptake of LCFA in cardiac myocytes and other cell types.28,29 We found that CD36 deficiency completely rescues the lipotoxic cardiomyopathy of MHC-PPARα mice. Surprisingly, however, the improvement of the lipotoxic cardiomyopathy correlated with a marked increase in myocardial glucose uptake and oxidation rather than significant changes in FA utilization.

Materials and Methods

Animal Experiments and Generation

A high-expressing MHC-PPARα transgenic mouse line (404-3)24 in C57BL/6 X CBA/J was back-crossed with C57BL/6 wild-type (WT) mice from The Jackson Laboratory (Bar Harbor, Me) for 6 generations, resulting in >95% C57BL/6 purity. MHC-PPARα mice were then crossed twice into the CD36-null (CD36−/−)28 background, resulting in MHC-PPARα/CD36−/− offspring. One-month-old mice were fed either a HF diet composed of 43% of calories from fat (TD 01381, Harlan Teklad, Madison, Wis) or acute insulin deficiency, states that result in increased delivery of nonesterified FA to the heart.27

Histologic Analyses

Immediately after harvest, a midventricular slice of myocardium was snap-frozen in a cryomold containing OCT for sectioning. To detect neutral lipid, frozen sections were stained with oil red O and counterstained with hematoxylin. Sectioning and staining was performed by the Morphology Core of the Digestive Diseases Research Core Center at the Washington University School of Medicine.

Analyses of Myocardial TAG

The quantitative analysis of myocardial TAG species by electrospray ionization mass spectrometry (ESI/MS) has been described.30,31

Echocardiographic Studies

Transhoracic M-mode and 2D echocardiograms were performed on conscious mice by using the Acuson Sequoia 256 Echocardiography System (Acuson, Mountain View, Calif), as described.32 Methods for measurements and chamber size using M-mode have been described.32

Northern and Western Blot Analyses

Total RNA was isolated by the RNAzol B method (Tel-Test, Friendswood Tex). Northern blot analyses were performed as described33 using radiolabeled cDNA probes. The cDNA for FA transporter protein 1 (FATP1) was kindly provided by Jean Schaffer (Washington University School of Medicine, St Louis, Mo). Quantitation was performed on a Storm phosphorimager (GE Healthcare, Piscataway, NJ) by scanning the band of interest and normalizing it to the level of 36B4. Western blot analyses were performed with cardiac whole-cell extracts as previously described34 by using antibodies against β-actin (Sigma, St Louis, Mo) and FATP1 (Santa Cruz Biotechnology, Santa Cruz, Calif).

Quantitative Real-Time RT-PCR Analyses

First-strand cDNA was generated by reverse transcription using total RNA from cardiac ventricles, Real-time RT-PCR was performed using TaqMan and SYBR Green reagents (Applied Biosystems, Foster City, Calif) on a 7500 Fast-Real Time PCR System (Applied Biosystems). The following primer and FAM/TAMRA probe sets were used: brain-type natriuretic peptide (forward, gctggttggggaatt; reverse, gcacggaggtctctct; probe, acctcgcttctccagctg); skeletal α-actin (forward, taatggctatccgagggtgctg; reverse, ccagcaactacaggaggttg); sarcomplastin/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) (forward, ggagatggatgcaacagctct; reverse, gcacggagcatctgctgg; probe, gtcaagctgtctggtgc); muscle-type carnitine palmitoyltransferase 1 (forward, tctaggcaatgccgttcac; reverse, gacacatgcacctgcaag; probe, tctcgatttctcacaacgg); uncoupling protein 3 (UCP3) (forward, tcggagtggctggagaatg; reverse, ccaaggccagagagtc; probe, aagttctctcatccatggtggagc); pyruvate dehydrogenase kinase 4 (PDK4) (forward, tggagctgcctggtgc; reverse, gcagccaggaggtcttccta; probe, cagtgcgttacagcgttgggac); PPARα (forward, actacggagttcacgcatgtg; reverse, ttgtcgtacaccagcttttt; probe, cgcctgccgcaagctgtcctg); PPARγ (forward, cctctggggtctgcagttctg; reverse, tggcagctgtctggtgg); PPARδ (forward, aagttctctcatccatggtggagc; reverse, cgcctgccgcaagctgtcctg; probe, cgcctgccgcaagctgtcctg).
Animals of each genotype group were born in the expected Mendelian ratios, and there were no significant differences in blood pressure, heart rate, or body weight between the genotypes (data not shown).

**CD36 Deficiency Prevents Myocardial Lipid Accumulation in MHC-PPARα Mice**

To determine the role of the LCFA transporter CD36 in the myocardial lipid accumulation that occurs in MHC-PPARα mice, the effects of a 4-week course of HF diet were analyzed. As expected, oil red O staining demonstrated a large accumulation of neutral lipid in the MHC-PPARα mice hearts compared with Wt controls (Figure 1A). In stark contrast, neutral lipid staining of the hearts of both CD36−/− and MHC-PPARα/CD36−/− mice was not different than that of the Wt mice (Figure 1A). Serum-free FA and TAG levels were not significantly different among the 4 genotypes, but serum cholesterol levels were slightly but significantly higher in the two CD36-deficient groups (Table 1).

Myocardial TAG content was characterized and quantified by ESI/MS in the 4 experimental groups. These data were consistent with the oil red O–staining patterns demonstrating significantly higher TAG levels in the MHC-PPARα hearts compared with that of MHC-PPARα/CD36−/− (Figure 1B). ESI/MS profiling of myocardial TAG species revealed that CD36 deficiency reversed the increased levels of esterified palmitic, stearic, oleic, and linoleic acids in the hearts of MHC-PPARα mice hearts (Figure 2A and 2B). These lipid species are enriched in the HF chow and their plasma levels are known to be highly influenced by diet. In contrast, there were no differences in the levels of other lipid species such as myristic, palmitoleic, and arachidonic acids, which are present in low levels in the HF chow (data not shown). These results, which are consistent with the oil red O–staining data, demonstrate that CD36 is necessary for the diet-induced TAG accumulation in MHC-PPAR hearts.

In addition to CD36, 2 other proteins, FATP1 and fatty acyl-CoA synthetase 1 (ACS1), have been shown to serve as LCFA transporters in the heart. Previously, we found that the expression of the FATP1 gene is higher in MHC-PPARα mice compared with Wt controls. Cardiac expression of the FATP1 gene remained modestly elevated in the MHC-PPARα/CD36−/− mice (Figure 3). ACS levels were not different among the genotypes (data not shown). Thus, the absence of CD36 in cardiac myocytes can prevent LCFA accumulation even in the context of increased FATP1 expression.

**CD36 Deficiency Rescues Cardiac Dysfunction but not Cardiac Hypertrophy in MHC-PPARα Mice**

Diabetic cardiomyopathy is characterized by ventricular hypertrophy, a phenotype that is also observed in the MHC-PPARα mice (Figure 4A). Interestingly, the biventricular to body weight ratio of 2-month old male CD36−/− mice was mildly but significantly increased compared with that of the Wt mice on standard or HF chow for four weeks. The biventricular to body weight of the MHC-PPARα/CD36−/− mice was not significantly different than that of the MHC-PPARα mice (Figure 4A). Consistent with the observed hypertrophic response, the expression of hypertrophic growth marker genes encoding brain-type natriuretic peptide and skeletal α-actin was increased in the MHC-PPARα, CD36−/−, and MHC-PPARα/CD36−/− mice compared with Wt controls (Figure 4B).

Echocardiography was performed on 2-month-old male Wt, MHC-PPARα, CD36−/−, and MHC-PPARα/CD36−/− mice receiving standard or HF chow to assess the impact of the CD36-deficient state on cardiac function. As expected, MHC-PPARα mice exhibited left ventricular (LV) systolic...
Figure 2. Decreased levels of myocardial LCFA species in MHC-PPARα/CD36−/− mice on HF diet. A, Representative neutral loss mass spectra based on ESI/MS analyses of oleic acid–containing TAG molecular species in lipid extracts prepared from the mouse lines indicated. Each spectrum is displayed normalized to the corresponding internal standard. The most abundant TAG molecular species as identified by “shotgun” lipidomics using multidimensional mass spectrometric analyses are indicated. B, Bars represent mean(±SEM) (Wt, n=3; CD36−/−, n=4; MHC-PPARα, n=5; MHC-PPARα/CD36−/−, n=3) levels of TAG-associated FAs with chain length of 16:0, 18:0, 18:1, and 18:2 in the hearts of male mice of each genotype after 4 weeks of HF diet, as determined by ESI/MS. *P<0.05.
CD36 Deficiency Rescues the Myocardial Glucose Metabolic Derangements in MHC-PPARα Mice

MHC-PPARα mice exhibit myocardial fuel utilization abnormalities that are similar to the diabetic heart; increased FA oxidation and reduced glucose utilization. To assess the metabolic correlates of the functional rescue conferred by CD36 deficiency, myocardial substrate oxidation rates were determined in the working mode in hearts isolated from 2-month-old mice of all 4 genotypes. Surprisingly, despite functional rescue, fatty acid oxidation rates were not significantly reduced in the MHC-PPARα/CD36−/− hearts compared with MHC-PPARα hearts (Figure 6A). In contrast, the CD36-deficient background reversed the reduction in glucose oxidation rates in MHC-PPARα hearts. Specifically, mean glucose oxidation rates in the MHC-PPARα/CD36−/− hearts were markedly increased (approximately 5-fold) to levels of the CD36−/− hearts, both being greater than the Wt hearts (Figure 6A).

The expression of genes involved in myocardial fuel utilization parallel the metabolic derangements in MHC-PPARα and diabetic mice; PPARα target genes involved in FA oxidation are activated, whereas myocyte glucose uptake and oxidation programs are downregulated.24,39,40 Therefore, we examined the expression of a subset of genes known to be involved in myocardial fuel metabolism in the MHC-PPARα/CD36−/− mice. Consistent with the results of the metabolic flux studies, the expression of PPARα target genes involved in mitochondrial (muscle-type carnitine palmitoyltransferase 1) and peroxisomal (acyl-CoA oxidase) fat oxidation pathways remained increased in both MHC-PPARα and MHC-PPARα/CD36−/− hearts compared with Wt and CD36−/− lines (Figure 6B). Expression of the mitochondrial UCP2 and UCP3, known PPARα target genes, were also activated to a similar extent in the hearts of MHC-PPARα and MHC-PPARα/CD36−/− mice (Figure 6B). In contrast, the expression of the glucose transporter GLUT4 and the negative regulator of glucose oxidation PDK4 was normalized in the MHC-PPARα/CD36−/− hearts (Figure 6C). Taken together, these results indicate that CD36 deficiency results in a reversal of the gene regulatory and metabolic derangements in glucose utilization but not FA oxidation in the CD36-deficient background. These findings also suggest that only a subset of the gene targets downstream of PPARα are deactivated in the context of CD36 deficiency.

Discussion

The PPARα gene regulatory pathway has been identified as a driver of the metabolic derangements contributing to insulin-resistant and insulin-deficient forms of diabetic cardiomyopathy. MHC-PPARα mice exhibit metabolic and functional signatures of the diabetic heart, including increased myocardial uptake and oxidation of FAs, myocyte TAG accumulation, reduced glucose utilization, and cardiomyopathy. This study was performed to determine whether a genetic manipulation aimed at reducing myocardial LCFA import would affect the lipotoxic cardiomyopathic phenotype of MHC-PPARα mice. The results were striking; the absence of CD36 completely rescued the myocardial neutral lipid imbalance and cardiac dysfunction of MHC-PPARα mice.

One of the signatures of lipotoxic forms of cardiomyopathy is myocyte lipid accumulation. CD36 deficiency prevented myocardial TAG accumulation in MHC-PPARα mice, even in the context of HF diet. This result was somewhat surprising given the existence of other cardiac FA transporters including FATP1 and ACS1. Our findings provide additional evidence for the importance of CD36 as a bona fide cardiac FA transporter in the heart. However, these results do not exclude the potential importance of other cardiac FA transporters. Previous studies have shown that transgenic overexpression of either ACS1 and/or FATP1 leads to increased cardiac...
It is possible that each transporter mediates FA import in response to a specific physiologic or nutritional milieu. Alternatively, CD36 could function in series rather than in parallel with the other proteins implicated in the transport process including FATP1 and ACS1. In this latter model, CD36 would serve as an indispensable component of the FA cellular transport system. Future loss-of-function studies aimed at each of the other cellular transport proteins alone and in combination with CD36 deficiency will be necessary to further define the physiological role and relevant interactions among the FA transporters.

Lipotoxic cardiomyopathy has been described in animal models of obesity and diabetes. In addition, humans with inborn errors in mitochondrial FA oxidation also develop cardiomyopathy associated with myocyte lipid accumulation. Proposed mechanisms for the development of cardiac dysfunction secondary to myocyte lipid overload include: (1) lipoapoptosis via ceramide-dependent pathways, (2) generation of reactive oxygen species via increased flux through mitochondrial and peroxisomal pathways, and (3) increased rates of oxygen consumption related to excessive mitochondrial FA oxidation. The results shown here provide additional evidence for a tight association between excessive lipid uptake and cardiac dysfunction. The rescue of the cardiomyopathy phenotype was associated with reversal of myocyte TAG accumulation. Surprisingly, however, the functional rescue did not significantly change FA oxidation rates; rather, it correlated with increased rates of glucose oxidation. This latter finding was also reflected at the gene expression level.

Figure 4. CD36 deficiency does not rescue the cardiac hypertrophic phenotype of MHC-PPARα mice. A, Bars represent mean(±SEM) biventricular to body weight (BV/BW) ratio for 2-month-old male Wt, CD36−/−, MHC-PPARα, and MHC-PPARα/CD36−/− mice fed standard or HF diet for 4 weeks (Wt on standard diet, n=18; CD36−/− on standard diet, n=15; MHC-PPARα on standard diet, n=10; MHC-PPARα/CD36−/− on standard diet, n=10; Wt on HF diet, n=15; CD36−/− on HF diet, n=15; MHC-PPARα on HF diet, n=13; MHC-PPARα/CD36−/− on HF diet, n=10). *P<0.05 vs Wt on matched corresponding diet. B, Hypertrophy gene markers are activated in the hearts of the CD36−/−, MHC-PPARα, and MHC-PPARα/CD36−/− mice. Graphs represent the mean(±SEM) (Wt, n=4; CD36−/−, n=4; MHC-PPARα, n=8; MHC-PPARα/CD36−/−, n=7) mRNA levels of brain-type natriuretic peptide (BNP), skeletal α-actin, and SERCA2a from the hearts of each genotype, as determined by real-time RT-PCR. Values shown are corrected to 36B4 and normalized (1.0) to Wt values. *P<0.05 vs Wt. AU, arbitrary units.

myocyte lipid import. It is possible that each transporter mediates FA import in response to a specific physiologic or nutritional milieu. Alternatively, CD36 could function in series rather than in parallel with the other proteins implicated in the transport process including FATP1 and ACS1. In this latter model, CD36 would serve as an indispensable component of the FA cellular transport system. Future loss-of-function studies aimed at each of the other cellular transport proteins alone and in combination with CD36 deficiency will be necessary to further define the physiological role and relevant interactions among the FA transporters.

Lipotoxic cardiomyopathy has been described in animal models of obesity and diabetes. In addition, humans with inborn errors in mitochondrial FA oxidation also develop cardiomyopathy associated with myocyte lipid accumulation. Proposed mechanisms for the development of cardiac dysfunction secondary to myocyte lipid overload include: (1) lipoapoptosis via ceramide-dependent pathways, (2) generation of reactive oxygen species via increased flux through mitochondrial and peroxisomal pathways, and (3) increased rates of oxygen consumption related to excessive mitochondrial FA oxidation. The results shown here provide additional evidence for a tight association between excessive lipid uptake and cardiac dysfunction. The rescue of the cardiomyopathy phenotype was associated with reversal of myocyte TAG accumulation. Surprisingly, however, the functional rescue did not significantly change FA oxidation rates; rather, it correlated with increased rates of glucose oxidation. This latter finding was also reflected at the gene expression level. Previous studies have demonstrated a link between reduced cardiac glucose oxidation and diabetic cardiac dysfunction, an association that is particularly relevant following ischemic
Metabolic modulation strategies aimed at increasing myocardial glucose oxidation have been shown to have improved functional recovery following ischemia/reperfusion. Thus, a possible explanation for the rescue of the LV dysfunction in the MHC-PPARα/H9251 mice is that CD36 deficiency reverses the suppression of myocardial glucose uptake and oxidation. Future studies aimed at the mechanism underlying this link are necessary to substantiate this conclusion. The observed reduction in neutral lipid stores could also be relevant. Although it would seem unlikely that the stored TAG is directly toxic to the myocyte, toxic byproducts of nonmitochondrial LCFA metabolism could be reduced by CD36 deficiency. In addition, increased import of LCFA can drive hydrogen peroxide production through the peroxisomal pathway, resulting in oxidative stress to the cardiac myocytes. Although the absence of CD36 rescued the cardiac dysfunction, it did not alter the cardiac hypertrophy of the MHC-PPARα mice; in fact, CD36 deficiency itself triggers a modest hypertrophic response. Interestingly, human studies have demonstrated a link between CD36 deficiency and cardiac hypertrophy. The connection between altered myocardial fuel flexibility and cardiac hypertrophic growth is well described; yet the mechanism remains elusive.

We were surprised to find that activation of PPARα target genes involved in FA oxidation were unchanged in the MHC-PPARα mice in a CD36-null background. Although the exact ligand for PPARα is not known, it is likely a LCFA derivative. Accordingly, despite markedly reduced rates of...
myocyte FA import, PPARα ligand is still available in the CD36-deficient mice. However, the reversal of the PPARα-mediated suppression of GLUT4 gene expression and activation of PDK4, a key negative regulator of glucose oxidation, in the MHC-PPARα/CD36−/− mice indicates that a subset of PPARα target genes was deactivated in the absence of CD36. This interesting result suggests the existence of target gene–specific thresholds for PPARα-mediated transcriptional control. It should be noted that the precise events involved in PPARα-mediated regulation of GLUT4 and PDK4 gene expression have not been delineated but the absence of known PPARα response elements in the promoter region of either gene suggests indirect mechanisms.

The observation that palmitate oxidation rates in the hearts of MHC-PPARα/CD36−/− mice are not different than that of MHC-PPARα mice raises the question of how FA oxidation is maintained, when presumably less LCFA is delivered in the absence of CD36. It is believed that the translocation of
LCFA across the plasma membrane is achieved by multiple mechanisms including diffusion (e.g., flip–flop mechanism) and by protein-mediated transport (e.g., FATP).49–53 Furthermore, FA metabolism influences the rate of FA uptake.53,54 Thus, the MHC-PPARα/CD36−/− mice could maintain high levels of FA oxidation by upregulating genes involved in the β-oxidation cycle in conjunction with CD36-independent LCFA uptake. The maintenance of palmitate oxidation in the hearts of MHC-PPARα/CD36−/− mice also raises the question of how the electron transport chain and ATP synthesis machinery copes with increased delivery of reducing equivalents. The most likely explanation is that respiratory uncoupling is increased in the hearts of the MHC-PPARα/CD36−/− mice. Consistent with this possibility, both UCP2 and UCP3 gene expression is increased in these hearts.

In conclusion, our results demonstrate that CD36 deficiency rescues a lipotoxic form of cardiomyopathy, as modeled by MHC-PPARα mice. The functional improvement of cardiac function conferred by CD36 deficiency was mirrored by reversal of myocardial lipid accumulation and a shift to reliance on glucose as a fuel source. If our results prove relevant in humans, CD36, as a glycoprotein cell surface receptor, shows promise as a new therapeutic target for prevention and treatment of cardiac dysfunction related to metabolic diseases such as obesity and diabetes. However, given that CD36 deficiency triggered mild cardiac hypertrophy and increased serum cholesterol level, future studies aimed at understanding the mechanisms linking CD36, cardiac fuel metabolism, and cardiac hypertrophic growth are warranted.

Acknowledgments
We thank Juliet Fong and Deanna Young for help with mouse husbandry and Mary Wingate and Teresa C. Leone for assistance with manuscript preparation.

Sources of Funding
This work was supported by NIH grants P01 HL57278, P50 HL077113, and KO8 HL076452. The Digestive Diseases Research Core Center is funded by NIH grant P30 DK52574; the Clinical Nutrition Research Unit Core Center, by NIH grant P30 DK56341.

Disclosures
D.P.K. is a scientific consultant for GlaxoSmithKline, Novartis, and Phrixus Inc.

References
CD36 Deficiency Rescues Lipotoxic Cardiomyopathy
John Yang, Nandakumar Sambandam, Xianlin Han, Richard W. Gross, Michael Courtois, Attila Kovacs, Maria Febbraio, Brian N. Finck and Daniel P. Kelly

_Circ Res._ 2007;100:1208-1217; originally published online March 15, 2007; doi: 10.1161/01.RES.0000264104.25265.b6

_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/100/8/1208

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2007/03/15/01.RES.0000264104.25265.b6.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:
http://circres.ahajournals.org/subscriptions/
Figure S1. Characterization of PPARα overexpression. The bars represent mean (±SEM) mRNA levels of PPARα as determined by real-time RT-PCR using RNA isolated from heart ventricles of Wt, CD36-/-, MHC-PPARα, and MHC-PPARα/CD36-/- male mice (n=5 per group). Values shown are corrected by 36B4 and normalized (=1.0) to Wt mice. *, $P<0.05$. 